Art. -Nr.: HY-B0268

Enoxacin

(Synonyms: AT 2266; CI 919)

2 Cited Publications

Kundenbewertung

Based on 2 publication(s) in Google Scholar

Enoxacin (AT 2266), a fluoroquinolone, interferes with DNA replication and inhibits bacterial DNA gyrase (IC₅₀=126 µg/ml) and topoisomerase IV (IC₅₀=26.5 µg/ml). Enoxacin is a miRNA processing activator and enhances siRNA-mediated mRNA degradation and promotes the biogenesis of endogenous miRNAs. Enoxacin has potent activities against gram-positive and -negative bacteria. Enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2 (TRBP)-mediated microRNA processing.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.14%
CAS. Nr.: 74011-58-8
Formel: C₁₅H₁₇FN₄O₃
Molecular Weight:320.32

Speicherung:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Enoxacin Chemical Structure

CAS. Nr.: 74011-58-8

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (2)
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

Quinolone

Alle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen :

Alle Antibiotic Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A-431	IC₅₀	>128 μM Compound: ENX	Anticancer activity against human A-431 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Anticancer activity against human A-431 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31881454]
A-431	IC₅₀	137 μM Compound: Enoxacin	Cytotoxicity against human A431 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human A431 cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
A-431	IC₅₀	150 μM Compound: Enoxacin	Inhibition of human A431 cell proliferation by MTT assay Inhibition of human A431 cell proliferation by MTT assay	[PMID: 19595598]
DU-145	EC₅₀	141 μM Compound: Enoxacin	Growth inhibition of human DU145 cells incubated for 72 hrs by MTT assay Growth inhibition of human DU145 cells incubated for 72 hrs by MTT assay	[PMID: 32672457]
EJ	IC₅₀	>128 μM Compound: ENX	Anticancer activity against human EJ cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Anticancer activity against human EJ cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31881454]
EJ	IC₅₀	137 μM Compound: Enoxacin	Cytotoxicity against human EJ cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human EJ cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
EJ	IC₅₀	178 μM Compound: Enoxacin	Inhibition of human EJ cell proliferation by MTT assay Inhibition of human EJ cell proliferation by MTT assay	[PMID: 19595598]
HCT-116	EC₅₀	124 μM Compound: 1	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 30108932]
HCT-116	EC₅₀	124 μM Compound: Enoxacin	Anticancer activity against human HCT116 cells incubated for 5 days by MTT assay Anticancer activity against human HCT116 cells incubated for 5 days by MTT assay	[PMID: 32672457]
HeLa	IC₅₀	170 μM Compound: Enoxacin	Inhibition of human HeLa cell proliferation Inhibition of human HeLa cell proliferation	[PMID: 19595598]
HeLa	IC₅₀	25.77 μM Compound: Enoxacin	Antiproliferative activity against human HeLa cells assessed as increase in miR-21 biogenesis level measured after 24 hrs by luciferase assay Antiproliferative activity against human HeLa cells assessed as increase in miR-21 biogenesis level measured after 24 hrs by luciferase assay	[PMID: 34038111]
KB	IC₅₀	>128 μM Compound: ENX	Anticancer activity against human KB cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Anticancer activity against human KB cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31881454]
KB	IC₅₀	137 μM Compound: Enoxacin	Inhibition of human KB cell proliferation by MTT assay Inhibition of human KB cell proliferation by MTT assay	[PMID: 19595598]
LNCaP	EC₅₀	105 μM Compound: Enoxacin	Growth inhibition of human LNCaP cells incubated for 72 hrs by MTT assay Growth inhibition of human LNCaP cells incubated for 72 hrs by MTT assay	[PMID: 32672457]
MCF7	IC₅₀	>128 μM Compound: ENX	Anticancer activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Anticancer activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31881454]
MCF7	IC₅₀	137 μM Compound: Enoxacin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
MCF7	IC₅₀	193 μM Compound: Enoxacin	Inhibition of human MCF7 cell proliferation by MTT assay Inhibition of human MCF7 cell proliferation by MTT assay	[PMID: 19595598]
NCI-H460	IC₅₀	36 μM Compound: Enoxacin	Inhibition of human NCI-H460 cell proliferation by sulphorodhamine B assay Inhibition of human NCI-H460 cell proliferation by sulphorodhamine B assay	[PMID: 19595598]
SK-HEP1	IC₅₀	25.03 μM Compound: Enoxacin	Antiproliferative activity against human SK-HEP1 cells incubated for 24 hrs by alamar blue assay Antiproliferative activity against human SK-HEP1 cells incubated for 24 hrs by alamar blue assay	[PMID: 34038111]
SK-MEL	IC₅₀	196 μM Compound: Enoxacin	Inhibition of human SK-MEL cell proliferation by MTT assay Inhibition of human SK-MEL cell proliferation by MTT assay	[PMID: 19595598]
SK-MEL3	IC₅₀	>128 μM Compound: ENX	Anticancer activity against human SK-MEL3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Anticancer activity against human SK-MEL3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31881454]
SK-MEL3	IC₅₀	137 μM Compound: Enoxacin	Cytotoxicity against human SK-MEL-3 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human SK-MEL-3 cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
SW480	IC₅₀	>128 μM Compound: ENX	Anticancer activity against human SW480 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Anticancer activity against human SW480 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31881454]
SW480	IC₅₀	137 μM Compound: Enoxacin	Cytotoxicity against human SW480 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human SW480 cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
SW480	IC₅₀	159 μM Compound: Enoxacin	Inhibition of human SW480 cell proliferation by MTT assay Inhibition of human SW480 cell proliferation by MTT assay	[PMID: 19595598]

In Vitro

Enoxacin (AT 2266) increases siGFP-mediated gene knockdown mediated by siRNA against EGFP in HEK293 cells-based reporter system in a dose-dependent manner, with a median effective concentration (EC50) of ~30 µM, whereas it has no effect on the cells expressing GFP only. Enoxacin (50 µM) promotes the processing of miRNAs and the loading of siRNA duplexes onto RISCs in HEK293 cells^[3].
Enoxacin has no effect on the processing of pre-let-7 or pre-miR-30a by Dicer alone. However, the addition of Enoxacin can enhance the processing of let-7 or pre-miR-30a by Dicer and TRBP together^[3].
Enoxacin inhibits 90% Escherichia coli, Klebsiella sp., Aeromonas sp., Enterobacter spp., Serratia spp., Proteus mirabilis, and Morganella morganii at less than or equal to 0.8 micrograms/ml^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Enoxacin (AT 2266; 100 µM; 2 µl; injected into ear once a day for 3 consecutive days (days 12, 13 and 14)) enhances the the GFP mRNA knockdown efficiency by Lv-siGFP (from 80% to 60%; 40% GFP mRNA level remained), whereas alone has no effect on GFP expression in GFP transgenic line C57BL/6-Tg(ACTB-EGFP)1Osb/J (10 d old) with lentivirus expressing shGFP (Lv-siGFP; injected into ear for 10 days)^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 74011-58-8
Appearance Solid
Molecular Weight 320.32
Formel C₁₅H₁₇FN₄O₃
Color White to light yellow
SMILES

O=C(C1=CN(CC)C2=C(C=C(F)C(N3CCNCC3)=N2)C1=O)O
Synonyms

AT 2266; CI 919
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (2)

All

Sort by:

Journal Impact Factor

Int J Biol Macromol

Reticuline isomerase AKR1B1 with aldo-keto reductase activity and detoxification function from the insect Blaps rhynchopetera. [Abstract]

2026 Mar:352:151224. PMID: 41791543
Sci Rep

Non-chemotherapy adjuvant agents in TP53 mutant Ewing sarcoma. [Abstract]

2023 Sep 1;13(1):14360. PMID: 37658148

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (273 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Sonia Melo, et al.Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing. Proc Natl Acad Sci U S A. 2011 Mar 15;108(11):4394-9. [Content Brief]

[2]. M Takei, et al. Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition. Antimicrob Agents Chemother. 2001 Dec;45(12):3544-7. [Content Brief]

[3]. Ge Shan, et al. A small molecule enhances RNA interference and promotes microRNA processing. Nat Biotechnol. 2008 Aug;26(8):933-40. [Content Brief]

[4]. Rengen Fan, et al. Small molecules with big roles in microRNA chemical biology and microRNA-targeted therapeutics. RNA Biol. 2019 Jun;16(6):707-718. [Content Brief]

[5]. Chin, N.-X. and H.C. Neu, In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprim. Antimicrobial agents and chemotherapy, 1983. 24(5): p. 754-763. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Enoxacin

2 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Enoxacin

Anti-Infection Compound Library

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Antibacterial Compound Library

NMPA-Approved Drug Library

FDA Approved & Pharmacopeial Drug Library

Antibiotics Library

Rare Diseases Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Withdrawn Drug Compound Library

Off-patent Drug Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

RNA Binding Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Enoxacin

Alle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen

Alle Antibiotic Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (2)

Reinheit & Dokumentation

Verweise

Calculators

Help & FAQs

Enoxacin

Anti-Infection Compound Library

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Antibacterial Compound Library

NMPA-Approved Drug Library

FDA Approved & Pharmacopeial Drug Library

Antibiotics Library

Rare Diseases Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Withdrawn Drug Compound Library

Off-patent Drug Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

RNA Binding Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Enoxacin

Alle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen

Alle Antibiotic Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (2)

Reinheit & Dokumentation

Verweise

Calculators

Help & FAQs

Enoxacin Related Classifications

HY-B0268 Related Classifications